Team

Jonathan Cohen

Jonathan Cohen

Founder, CEO

Jonathan Cohen, Founder, President, and CEO: Under Mr. Cohen’s leadership, 20/20 GeneSystems has brought in approximately $7.5 million in grant funding and launched two successful products, a kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer. He is the co-inventor of an AI approach for improving tumor biomarker accuracy that is covered in a pending PCT International Patent Application. As 20/20’s CEO, Mr. Cohen forged strategic alliances with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics, Smiths Detection, and Ping An Ventures, the investment arm of the largest insurance company in China. Active in public policy initiatives on behalf of the biotechnology industry, Mr. Cohen conceived of and helped bring about the passage of the Maryland Biotechnology Investment Tax Credit. Mr. Cohen is a founding director of the Small Biotechnology Business Coalition. Before founding 20/20, Mr. Cohen was patent and general counsel for two publicly traded companies: Ventana Medical Systems Inc. (acquired by Roche diagnostics in 2008 for $3.4 billioni) and Oncor Inc. Mr. Cohen is a registered patent attorney with more than 18 years of experience in biotechnology patents and licensing matters. He has a Master of Science in Biotechnology from Johns Hopkins University and a law degree from the American University.

David Schodin, PhD

David Schodin, PhD

Business Development, U.S.

Dr. Schodin is a PhD scientist with 10 years’ experience in academic biochemical research and is an experienced lawyer, having worked at a private law firm and the Abbott Laboratories legal division. He started off at Abbott as Senior Patent Counsel as a client-facing patent attorney for the Abbott Pharmaceuticals Oncology and Pain therapeutic teams. He became the Director of Business Development and Licensing at Abbott Molecular where he was the lead negotiator and drafter. He worked on intellectual property settlements, licenses, corporate partnering agreements, non-standard supply agreements, and research and development agreements. Additionally, he led initiatives to incorporate cutting-edge technologies and key product assets into the business technology portfolio. Dr. Schodin holds a bachelor’s degree in Chemistry from Knox College, a PhD in Biochemistry from the University of Illinois at Urbana-Champaign, and a JD from Illinois Institute of Technology.

Hunter Chen

Hunter Chen

Business Development, China

Hunter is a co-founder of Med Qiao Group LLC, a unique strategic consulting firm and investor in the healthcare industry. Prior to joining Med Qiao, Hunter was one of the major contractors at Aubridge Partners, a New York-based strategic consulting firm helping U.S. companies venture into the Chinese market. He managed more than 10 middle-sized U.S. companies’ China operations including sales, sourcing, manufacturing, fundraising, and mergers and acquisitions. Before Aubridge, Hunter was a Senior Project Manager for the SC Johnson R&D center, based in Racine, Wisconsin. Hunter helped SC Johnson redesign products and produce for large-volume manufacturing with a well-functioning quality control system. Hunter has four bachelor degrees in

Engineering, Finance, English Language, and Computer Science. He is also a charted ISO13495 and ISO9001 auditor (Medical Device Manufacturing) and is currently undergoing pathology training at a medical school in Shanghai during his spare time.

Thomas Dann

Thomas Dann

Finance and Corporate Strategy

Tom is also Managing Director of Castlehaven Advisors, LLC, advising venture funds and technology companies, and serves as Chief Investment Officer of Cellphire, Inc., a biotech company developing a platelet substitute with broad applications in trauma, anti-coagulent reversal, orthopedics, wound care, imaging and targeted drug delivery. Mr. Dann is an experienced venture investor, formerly Managing Director of the Maryland Venture Fund, the $120M venture program funded by Maryland which has invested into private venture funds as well as scores of start-ups and early stage companies across a wide range of industry sectors. Dann’s professional career has been focused on venture investing, private equity, and public and private initiatives to foster entrepreneurship and job creation. Dann previously founded ECentury Capital Partners, a $90 million early stage venture fund where he served as managing director and general counsel, and he was a Venture Partner and Director of GIV Venture Partners. Mr. Dann holds a B.A. from Stanford University and a JD from the American University Law School. He is a member of the Maryland, California and District of Columbia Bars.

Barry Cohen

Barry Cohen

Software Development

Barry Cohen, Software Development: Barry is currently the Director of Global Business Development at 20/20 GeneSystems. Barry has worked at 20/20 for almost 10 years and previously served as the Director of Sales for the lung cancer test. Prior to joining 20/20, he worked at apparel manufacturer Hartz & Company where he served as the Vice President of Manufacturing, managing two manufacturing facilities in Maryland and Virginia with over 500 employees. He then went on to become the President of Hartz & Company, managing the sale of its business units, assets, and trade names after over 100 years of apparel manufacturing in the U.S. Barry holds a bachelor’s degree in Computer Science from Tulane University.

Jeffrey Allard, PhD

Jeffrey Allard, PhD

Clinical Affairs

Dr. Allard is a biochemist and is President of Lakeside Life Science, which provides consulting services and biospecimens to the biotechnology industry. He served most recently as Director of Development for Caris Life Sciences, where he designed and implemented a Product Development System, designed multiple clinical and regulatory strategies for novel multiplex oncology tests, wrote clinical protocols for prospective research and Premarket Approval (PMA)-submission trials, and designed a patient registry. As Vice President and Chief Scientific Officer of Fujirebio Diagnostics, Inc. (FDI), Dr. Allard directed the Applied Research, Product Development, Clinical Affairs, Regulatory Affairs, and Process Engineering departments. Prior to joining FDI in 2004, Dr. Allard previously held positions as Vice President of Clinical Research and Development for Immunicon Corporation (Currently Veridex LLC, a division of Johnson & Johnson) where he designed and managed clinical trials that led to the worldwide introduction of the CellSearch Assay for measurement of circulating tumor cells (CTC). Dr. Allard designed three clinical trials that led to FDA clearance of CTC for prediction of overall survival and progression free survival in patients with breast, colorectal, and prostate cancers. Dr. Allard is an inventor on 12 patents for novel technologies, including new tests for gynecologic cancers, circulating tumor cells, complexed PSA for early detection of prostate cancer, and other diagnostic technologies. He is an author of over 50 manuscripts and has received numerous awards including the Professional Achievement Award from Idaho State
University.

Dr. Allard holds a PhD in Biochemistry from Dartmouth College and a master’s degree in Immunology from Idaho State University.

Victoria Doseeva, PhD

Victoria Doseeva, PhD

Director of Diagnostics Development

Dr. Doseeva managed pre-clinical and clinical studies of the CLIA-certified lung cancer test using retrospective and prospective patient serum samples and was able to improve its clinical sensitivity and diagnostic accuracy. Her recent accomplishments include analytical and clinical validation of a multiplexed Luminex-based immunoassay for the early detection of lung cancer under GLP and CLIA regulations. Dr. Doseeva has a wide range of experience in the biotechnology industry, having managed groups in diagnostic assay development, analytical methods development, protein production, and characterization, as well as having led a research and development group in support of development and validation of cancer diagnostics assays and companion diagnostic tests for molecularly targeted cancer drugs. Notably, from 2007 to 2012 she worked at Qiagen in Gaithersburg, Maryland as an assay development manager. At Qiagen, she managed a team of scientists that successfully designed and developed several novel diagnostic assays. For example, she was the principal investigator in the design and development of novel DNA amplification assays for the rapid and sensitive detection of various pathogens. Additionally, Dr. Doseeva has published 27 journal articles and co-authored two patent applications. Dr. Doseeva has a PhD in Biochemistry and a master’s degree in Chemistry from Moscow State University. She was a postdoctoral researcher at the National Cancer Institute, where she studied signal transduction pathways in cancer, and at Georgetown University Medical Center, where she studied DNA replication and recombination.

 Michael S. Lebowitz, PhD

Michael S. Lebowitz, PhD

BioAnalytics

Dr. Lebowitz has more than 18 years of experience in biomedical research within the biotech industry having previously served as Vice President of Research at Ariadne Diagnostics, LLC. He has been directly involved in the commercial launch of six cancer diagnostic tests and the research leading up to a pharmaceutical IND approval. Dr. Lebowitz holds a Ph.D. from the Johns Hopkins University School of Medicine in Biochemistry, Cellular, and Molecular Biology where he subsequently completed a three-year fellowship in immunology in the Department of Pathology, Division of Immunopathology. He remains associated with JHU as an adjunct Lecturer in the Advanced Academic Program in Biotechnology within the Krieger School of Arts and Sciences.

Peter Shindell

Peter Shindell

Machine Learning / Bioinformatics

With 3 Masters in computer science, applied statistics and bioinformatics, Peter has more than 10 years of experience in data manipulation, data analysis, and predictive modeling as a statistician and data scientist. He also has extensive experience in clinical trial, PB/PD modeling, and Artificial Intelligence. Mr. Shindell has extensive experience in statistical methods to multi-source data and survey data including logistic regression, multiple regressions, mixture model, time series analysis, non-linear regression, CART, Bayesian network etc.,

With MS degrees in Biology/ Bioinformatics, Applied Statistics, and Computer Information Systems, he is currently a PhD student in Artificial Intelligence/Data mining with the degree expected in 2018.

Dr. Suzana Radulovich

Dr. Suzana Radulovich

CLIA Medical Director

Dr. Suzana Radulovich, CLIA Medical Director: Dr. Suzana Radulovich joined the 20/20 GeneSystems team as Laboratory Medical Director in 2014. Dr. Radulovich has over 15 years of expertise in clinical microbiology and development of diagnostic methods, bacterial pathogenesis, and molecular biology, coupled with the experience in the treatment of the infectious diseases. Dr. Radulovich obtained her medical degree at University of Ljubljana, School of Medicine. She moved to the U.S. in 1992 to pursue postdoctoral training in the areas of infectious diseases, clinical diagnostics, microbiology,immunology, and pathogenesis at the University of Texas Medical Branch at Galveston (1992-1995). In 1995, Dr. Radulovich joined University of Maryland School of Medicine in Baltimore. There, she became the Assistant Professor of Microbiology and Immunology in 1998. She earned the Associate Professorship title in 2004. In 2009, together with Dr. Bala, she established the Bala Family Practice in Bel Air, Maryland, where she practices and leads all clinical diagnostic testing as their Laboratory Medical Director.

Phil Graves

Phil Graves

Webmaster, Digital Marketing

Mr. Graves has been a web and graphic designer for more than 15 years. His primary responsibility include maintaining the group of company websites and helping manage our various social media outlets.

Michael Ross, M.D.

Board Member

Dr. Ross is the Chairman and CEO of Euclid Systems Corporation (Herndon, VA) where he led the growth of this ophthalmic medical device company from $3.1 million to over $8.1 million in revenue in only years. The bulk of Euclid’s sales are in China and East Asia where Michael visits 4-5 times per year. (He has participated in meetings with 20/20 and Chinese hospital collaborators.) Prior to joining Euclid, he was CEO of E-P Therapeutics, and was a Medical and Scientific Advisor to StemCyte, Inc. Michael was elected to the board of the Generic Pharmaceuticals Association by my peers after only two years in the industry. Board certified in Obstetrics and Gynecology he was a founding member of a OB-GYN-Infertility practice in Northern Virginia From 1980 through 2007. Dr. Ross has been a Clinical Professor of Obstetrics and Gynecology, George Washington University Medical Center since 1979 and has served on the Boards of Directors of several biotech and medical device companies.

He Shen

Board Member

Mr. He Shen has 20 years of investment banking experiences in New York and London, with expertise in private equity, structured capital markets, regulatory capital, corporate finance and derivatives. Most recently, Mr. Shen was retained by Australian and New Zealand Banking Group and China Blue Focus Communications Group to advise their international CEOs on capital and balance sheet optimization. In the meantime, Mr. Shen has been actively involved in Keiretsu Forum, one of the world’s largest angel investor networks, and has invested in over 20 companies ranging from consumer products to software and biotechnologies during the past year.

Until 2015, Mr. Shen spent 10 years at Lloyds Banking Group where he co-headed Strategic Transactions Group which included over 20 professionals with structured finance, legal, accounting, tax, and capital markets/derivatives expertise.

Prior to joining Lloyds Banking Group, Mr. Shen worked in the Global New Product Development Group of Merrill Lynch where he originated and developed cross border enhanced yield investment products for financial institutions globally, and he was also involved in structuring and executing innovative hybrid capital instruments for US and European banks and insurance companies.

Additionally, Mr. Shen worked in the Structured Products Group of Donaldson Lufkin & Jenrette / Credit Suisse where he was focused on product development, origination and execution of innovative debt and equity financing structures for investment banking clients with customized accounting / tax / regulatory / rating agency benefits.

John Compton, Ph.D

Board Member

Dr.  Compton, a 20/20 shareholder, serve as Scientific Director and Co-President of GeneDx Inc., the operating assets of which were acquired by BioReference Laboratories (now part of Opko) in September 2006. GeneDx is a world leader in Genomics with an acknowledged expertise in rare and ultra rare genetic disorders, as well as one of the broadest menus of sequencing services available among commercial laboratories. GeneDx provides testing to patients and their families in more than 55 countries. See http://www.genedx.com He has 25 years experience in the development and application of molecular biological techniques to answer questions about genetics and epidermal differentiation, and has authored more than 60 publications in the field. He holds B.S. degrees in Physics and Biology from MIT, received his Ph.D. from the University of California, Berkeley in Biophysics, and did his post-doctoral training in protein-DNA interactions at the Baylor College of Medicine. In 2003 they were jointly awarded the Entrepreneur of the Year award by the Technology Council of Maryland.

Richard M. Cohen, CPA

Board Member

Rich is an experienced CEO /CFO at public and private companies. His professional experience includes biotech, financial services and diversified media and he maintains excellent contacts with capital financing sources on and off Wall Street. He was the CEO, CFO, and Board Member of CorMedix Inc., Bridgewater, NJ (2010 – 2013) a publicly traded (NYSE) medical device/biotechnology company with intrapericardial therapy product targeted to markets in the U.S. and Europe. He has served on the Board of Directors of Helix BioMedix, Inc. – Audit Committee Chair (2006 – Present) CorMedix Inc. – Audit Committee Chair (2010 – 2013) and Rodman & Renshaw – Audit Committee Chair (2008 – 2012)

Cohen’s academic credentials include an MBA, Stanford University 1975, BS with honors, Wharton School, University of Pennsylvania.